 PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the full results from the SARA-INT Phase 2 trial of Sarconeos BIO101 in Sarcopenia that have been presented at the International Conference on Frailty and Sarcopenia Research ICFSR on September, 30th. ICFSR is the key international scientific event on Frailty and Sarcopenia and is attended by leading researchers, physicians and BiotechPharma in this field. 